Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial

Tannock, Ian; Fizazi, Karim; Ivanov, Sergey; Karlsson, Camilla; Flechon, Aude; Skoneczna, Iwona; Orlandi, Francisco; Gravis, Gwenaelle; Matveev, Vsevolod; Bavbek, Sevil; Gil, Thierry; Viana, Luciano; Aren, Osvaldo; Karyakin, Oleg; Elliott, Tony; Birtle, Alison; Magherini, Emmanuelle; Hatteville, Laurence; Petrylak, Daniel; Tombal, Bertrand; Rosenthal, Mark

doi:10.1016/s1470-2045(13)70184-0

Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial

Atıf İçin Kopyala

Tannock I. F., Fizazi K., Ivanov S., Karlsson C. T., Flechon A., Skoneczna I., ...Daha Fazla

LANCET ONCOLOGY, cilt.14, sa.8, ss.760-768, 2013 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 14 Sayı: 8
Basım Tarihi: 2013
Doi Numarası: 10.1016/s1470-2045(13)70184-0
Dergi Adı: LANCET ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.760-768
İstanbul Üniversitesi Adresli: Evet

Özet

Background Docetaxel plus prednisone is standard first-line chemotherapy for men with metastatic castrate-resistant prostate cancer. Aflibercept is a recombinant human fusion protein that binds A and B isoforms of VEGF and placental growth factor, thereby inhibiting angiogenesis. We assessed whether the addition of aflibercept to docetaxel and prednisone would improve overall survival in men with metastatic castrate-resistant prostate cancer compared with the addition of placebo to docetaxel and prednisone.